Showing results (101-110 of 124) with videos related to

Sort By:
Pageof 13
Breast Cancer (Tokyo, Japan)|June 17, 2026
Prognosis of ER-positive, HER2-negative postmenopausal early breast cancer patients based on response to neoadjuvant endocrine therapy and multigene assay results: findings from the NEOS trialHiroji Iwata, Norikazu Masuda, Yutaka Yamamoto, et al.
International Journal of Clinical Oncology|April 23, 2021
Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19)Kenjiro Aogi, Kenichi Watanabe, Masahiro Kitada, et al.
Diabetes|April 30, 2009
Confirmation of multiple risk Loci and genetic impacts by a genome-wide association study of type 2 diabetes in the Japanese populationFumihiko Takeuchi, Masakuni Serizawa, Ken Yamamoto, et al.
Human Immunology|October 3, 2003
Stromal-cell derived factor-1 chemokine gene variant is associated with type 1 diabetes age at onset in Japanese populationAkane Ide, Eiji Kawasaki, Norio Abiru, et al.
British Journal of Cancer|April 3, 2020
Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 studyHirofumi Mukai, Takeshi Yamaguchi, Masato Takahashi, et al.
Annals of Surgical Oncology|February 18, 2026
Radiofrequency Ablation for Early Stage Breast Cancer as a Potential Alternative to Partial Mastectomy: 5-Year Results from the Multiple-Center, Single-Arm, Phase 3 RAFAELO Study (NCCH1409)Takayuki Kinoshita, Shin Takayama, Tomomi Fujisawa, et al.
Breast (Edinburgh, Scotland)|April 30, 2026
Health-related quality of life with pertuzumab retreatment: Secondary analysis of the PRECIOUS trialNaruto Taira, Yutaka Yamamoto, Hiroji Iwata, et al.
International Journal of Clinical Oncology|January 22, 2026
Clinical complete response and predictive factors in HER2-positive early breast cancer treated with neoadjuvant chemotherapy aimed at omission of surgery: an exploratory analysis of the JCOG1806 trialHideo Shigematsu, Tomomi Fujisawa, Fumikata Hara, et al.
Japanese Journal of Clinical Oncology|July 19, 2018
A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS studyYutaka Yamamoto, Hiroji Iwata, Takayuki Ueno, et al.
Breast Cancer Research and Treatment|March 15, 2020
A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancerHiroshi Ishiguro, Norikazu Masuda, Nobuaki Sato, et al.
Pageof 13